The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma

International Journal of Molecular Medicine

Volumn 32, Issue 4, 2013, Pages 860-866

  Jeon, Young Joo ^a   Ko, Seon Mi ^a   Cho, Jin Hyoung ^a   Chae, Jung Il ^a   Shim, Jung Hyun ^b  

^a Chonbuk National University   (South Korea)

^b Mokpo National University   (South Korea)

Author keywords

Apoptosis; Histone deacetylase inhibitor; Oral squamous cell carcinoma; Panobinostat; Specificity protein 1

Indexed keywords

CASPASE 3; CYCLIN D1; PANOBINOSTAT; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P21; PROTEIN P27; SURVIVIN; SYNAPSIN I;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MOUTH NEOPLASMS; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84883340020     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1451     Document Type: Article

References (42)

1. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
2. Mashberg A, Boffetta P, Winkelman R and Garfinkel L: Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer 72: 1369-1375, 1993.
3. Neville BW and Day TA: Oral cancer and precancerous lesions. CA Cancer J Clin 52: 195-215, 2002.
4. Liang XH, Lewis J, Foote R, Smith D and Kademani D: Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience. J Oral Maxillofac Surg 66: 1875-1880, 2008.
5. Gordaliza M: Natural products as leads to anticancer drugs. Clin Transl Oncol 9: 767-776, 2007.
6. Rasheed WK, Johnstone RW and Prince HM: Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16: 659-678, 2007.
7. Vigushin DM and Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1-13, 2002.
8. Lin HY, Chen CS, Lin SP, Weng JR and Chen SC: Targeting histone deacetylase in cancer therapy. Med Res Rev 26: 397-413, 2006.
9. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
10. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
11. Johnstone RW and Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003
12. Atadja P: Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233-241, 2009.
13. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
14. Shao W, Growney JD, Feng Y, et al: Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer 127: 2199-2208, 2010.
15. Maiso P, Carvajal-Vergara X, Ocio EM, et al: The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66: 5781-5789, 2006.
16. Giles F, Fischer T, Cortes J, et al: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628-4635, 2006.
17. Gupta SC, Kim JH, Prasad S and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434, 2010.
18. Deniaud E, Baguet J, Mathieu AL, Pages G, Marvel J and Leverrier Y: Overexpression of Sp1 transcription factor induces apoptosis. Oncogene 25: 7096-7105, 2006.
19. Jutooru I, Chadalapaka G, Sreevalsan S, et al: Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res 316: 2174-2188, 2010.
20. Schmitt CA and Lowe SW: Apoptosis and therapy. J Pathol 187: 127-137, 1999.
21. Nagata S: Fas-induced apoptosis. Intern Med 37: 179-181, 1998.
22. Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell 102: 1-4, 2000.
23. Marks PA, Richon VM and Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216, 2000.
24. Miller TA, Witter DJ and Belvedere S: Histone deacetylase inhibitors. J Med Chem 46: 5097-5116, 2003.
25. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK and Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528, 2005.
26. Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51, 2006.
27. Chao H, Wang L, Hao J, et al: Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Lett 329: 17-26, 2013
28. Vallo S, Mani J, Stastny M, et al: The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs 31: 265-272, 2013.
29. Di Fazio P, Montalbano R, Neureiter D, et al: Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 318: 1832-1843, 2012.
30. Di Fazio P, Schneider-Stock R, Neureiter D, et al: The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 32: 285-300, 2010.
31. Chiefari E, Brunetti A, Arturi F, et al: Increased expression of AP 2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? BMC Cancer 2: 35, 2002.
32. Hosoi Y, Watanabe T, Nakagawa K, et al: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 25: 461-468, 2004.
33. Wang L, Wei D, Huang S, et al: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003.
34. Yao JC, Wang L, Wei D, et al: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 10: 4109-4117, 2004.
35. Zannetti A, Del Vecchio S, Carriero MV, et al: Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res 60: 1546-1551, 2000.
36. Davie JR, He S, Li L, et al: Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 48: 189-208, 2008.
37. Li L and Davie JR: The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 192: 275-283, 2010.
38. Duan H, Heckman CA and Boxer LM: Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619, 2005.
39. Wilson AJ, Chueh AC, Togel L, et al: Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res 70: 609-620, 2010.
40. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA and Miller DM: Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621, 1991.
41. Chintharlapalli S, Papineni S, Lei P, Pathi S and Safe S: Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. BMC Cancer 11: 371, 2011.
42. Pietrzak M and Puzianowska-Kuznicka M: p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter. Biol Chem 389: 383-393, 2008.